Advertisement
Screener

Processa Pharmaceuticals, Inc. (PCSA) Research and Development Expense

2.8 / 5 stars · 68/120 Roast Me

Processa Pharmaceuticals, Inc. Research and Development Expense

Processa Pharmaceuticals, Inc. (PCSA) reported Research and Development Expense of $5.80 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-29.

Discontinued › Expense Statement › Operating Expenses

us-gaap:ResearchAndDevelopmentExpense · last filed 2024-03-29

  • Processa Pharmaceuticals, Inc. research and development expense for the quarter ending 2022-03-31 was $2.04M, a 38.47% increase year-over-year.
  • Processa Pharmaceuticals, Inc. research and development expense for the quarter ending 2021-03-31 was $1.48M, a 194.19% increase year-over-year.
  • Processa Pharmaceuticals, Inc. research and development expense for the quarter ending 2020-12-31 was $1.71M, a 231.32% increase year-over-year.
  • Processa Pharmaceuticals, Inc. research and development expense for the quarter ending 2020-09-30 was $532.59K, a 8.96% decline year-over-year.
  • Processa Pharmaceuticals, Inc. research and development expense for fiscal 2023 was $5.80M, a 49.54% decline from fiscal 2022.
  • Processa Pharmaceuticals, Inc. research and development expense for fiscal 2022 was $11.49M, a 67.12% increase from fiscal 2021.
  • Processa Pharmaceuticals, Inc. research and development expense for fiscal 2021 was $6.88M, a 116.81% increase from fiscal 2020.
  • Processa Pharmaceuticals, Inc. research and development expense for fiscal 2020 was $3.17M, a 36.71% increase from fiscal 2019.
Period endResearch and Development Expense 3 monthResearch and Development Expense 3 month as first filedResearch and Development Expense 6 monthResearch and Development Expense 6 month as first filedResearch and Development Expense 9 monthResearch and Development Expense 9 month as first filedResearch and Development Expense 12 monthResearch and Development Expense 12 month as first filedResearch and Development Expense 27 monthResearch and Development Expense 30 monthResearch and Development Expense 33 monthResearch and Development Expense 36 month
2023-12-31$5.80M
10-K · filed 2024-03-29
2022-12-31$11.49M
10-K · filed 2024-03-29
2022-03-31$2.04M
10-Q · filed 2022-05-12
2021-12-31$6.88M
10-K · filed 2023-03-30
2021-03-31$1.48M
10-Q · filed 2022-05-12
$3.19M
derived: sum of 2 quarters · filed 2022-05-12
$3.72M
derived: sum of 3 quarters · filed 2022-05-12
$4.15M
derived: sum of 4 quarters · filed 2022-05-12
2020-12-31$1.71M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30
$2.24M
derived: sum of 2 quarters · filed 2022-03-30
$2.67M
derived: sum of 3 quarters · filed 2022-03-30
$3.17M
10-K · filed 2022-03-30
2020-09-30$532.59K
10-Q · filed 2020-11-12
$959.70K
derived: sum of 2 quarters · filed 2020-11-12
$1.46M
10-Q · filed 2020-11-12
$1.98M
derived: sum of 4 quarters · filed 2021-05-13
2020-06-30$427.11K
10-Q · filed 2020-08-05
$925.86K
10-Q · filed 2020-08-05
$1.45M
derived: sum of 3 quarters · filed 2021-05-13
$2.03M
derived: sum of 4 quarters · filed 2021-05-13
2020-03-31$501.77K
10-Q · filed 2021-05-13
$1.02M
derived: sum of 2 quarters · filed 2021-05-13
$1.60M
derived: sum of 3 quarters · filed 2021-05-13
$2.33M
derived: sum of 4 quarters · filed 2021-05-13
2019-12-31$516.40K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25
$1.10M
derived: sum of 2 quarters · filed 2021-03-25
$1.83M
derived: sum of 3 quarters · filed 2021-03-25
$2.32M
10-K · filed 2021-03-25
2019-09-30$584.98K
10-Q · filed 2020-11-12
$1.31M
derived: sum of 2 quarters · filed 2020-11-12
$1.80M
10-Q · filed 2020-11-12
$2.40M
derived: sum of 4 quarters · filed 2020-11-12
2019-06-30$726.90K
10-Q · filed 2020-08-05
$1.21M
10-Q · filed 2020-08-05
$1.82M
derived: sum of 3 quarters · filed 2020-08-05
$2.43M
derived: sum of 4 quarters · filed 2020-08-05
2019-03-31$484.75K
10-Q · filed 2020-05-15
$1.09M
derived: sum of 2 quarters · filed 2020-05-15
$1.70M
derived: sum of 3 quarters · filed 2020-05-15
$2.78M
derived: sum of 4 quarters · filed 2020-05-15
2018-12-31$607.84K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-06
$1.22M
derived: sum of 2 quarters · filed 2020-03-06
$2.30M
derived: sum of 3 quarters · filed 2020-03-06
$3.09M
10-K · filed 2020-03-06
2018-09-30$611.61K
10-Q · filed 2019-11-14
$1.69M
derived: sum of 2 quarters · filed 2019-11-14
$2.48M
10-Q · filed 2019-11-14
$2.70M
derived: sum of 4 quarters · filed 2019-11-14
2018-06-30$1.08M
10-Q · filed 2019-08-14
$1.87M
10-Q · filed 2019-08-14
$2.09M
derived: sum of 3 quarters · filed 2019-08-14
$2.55M
derived: sum of 4 quarters · filed 2019-08-14
2018-03-31$821.39K
10-Q · filed 2019-05-14
$807.66K
10-Q · filed 2018-05-21
$1.01M
derived: sum of 2 quarters · filed 2019-05-14
$1.47M
derived: sum of 3 quarters · filed 2019-05-14
$1.63M
derived: sum of 4 quarters · filed 2019-05-14
2017-12-31$191.63K
derived: 10-K/A 12 month − 10-Q 9 month · filed 2019-04-08
$649.26K
derived: sum of 2 quarters · filed 2019-04-08
$810.13K
derived: sum of 3 quarters · filed 2019-04-08
$964.16K
10-K/A · filed 2019-04-08
$926.12K
10-K · filed 2018-04-16
2017-09-30$457.63K
10-Q · filed 2018-11-14
$618.50K
derived: sum of 2 quarters · filed 2018-11-14
$772.53K
10-Q · filed 2018-11-14
$166.00
10-Q · filed 2017-11-20
$2.29M
derived: sum of 4 quarters · filed 2018-11-14
2017-06-30$160.87K
10-Q · filed 2018-08-14
$83.00
10-Q · filed 2017-10-04
$311.16K
10-Q · filed 2018-08-14
$166.00
10-Q · filed 2017-10-04
$1.83M
derived: sum of 3 quarters · filed 2018-08-14
$1.83M
derived: sum of 4 quarters · filed 2018-08-14
2017-03-31$139.92K
10-Q · filed 2018-05-21
$83.00
10-Q · filed 2017-10-04
$1.67M
derived: sum of 2 quarters · filed 2018-05-21
$1.67M
derived: sum of 3 quarters · filed 2018-05-21
$1.68M
derived: sum of 4 quarters · filed 2018-05-21
2016-12-31$1.53M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-16
$1.53M
derived: sum of 2 quarters · filed 2018-04-16
$1.54M
derived: sum of 3 quarters · filed 2018-04-16
$1.54M
10-K · filed 2018-04-16
$6.56K
10-K · filed 2017-09-25
2016-09-30$574.00
10-Q · filed 2017-11-20
$6.27K
derived: sum of 2 quarters · filed 2017-11-20
$6.27K
10-Q · filed 2017-11-20
2016-06-30$5.70K
10-Q · filed 2017-10-04
$5.70K
10-Q · filed 2017-10-04
2015-12-31$5.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-25
$6.71K
derived: sum of 2 quarters · filed 2017-09-25
$17.51K
derived: sum of 3 quarters · filed 2017-09-25
$29.25K
10-K · filed 2017-09-25
2015-09-30$1.71K
10-Q · filed 2017-09-08
$12.51K
derived: sum of 2 quarters · filed 2017-09-08
$24.25K
10-Q · filed 2017-09-08
$27.15K
10-Q · filed 2015-12-01
$22.34K
derived: sum of 4 quarters · filed 2017-09-08
2015-06-30$10.79K
10-Q · filed 2017-08-30
$10.98K
10-Q · filed 2015-08-19
$22.53K
10-Q · filed 2017-08-30
$25.43K
10-Q · filed 2015-08-19
$20.62K
derived: sum of 3 quarters · filed 2017-08-30
$32.35K
derived: sum of 4 quarters · filed 2017-08-30
2015-03-31$11.74K
10-Q · filed 2017-08-07
$14.45K
10-Q · filed 2015-05-15
$9.83K
derived: sum of 2 quarters · filed 2017-08-07
$21.56K
derived: sum of 3 quarters · filed 2017-08-07
$90.05K
derived: sum of 4 quarters · filed 2017-08-07
2014-12-31-$1.91K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-06-19
$9.82K
derived: sum of 2 quarters · filed 2017-06-19
$78.32K
derived: sum of 3 quarters · filed 2017-06-19
$178.09K
10-K · filed 2017-06-19
$189.75K
10-K · filed 2015-04-14
2014-09-30$11.73K
10-Q · filed 2015-12-01
$80.22K
derived: sum of 2 quarters · filed 2015-12-01
$179.99K
10-Q · filed 2015-12-01
$256.60K
derived: sum of 4 quarters · filed 2015-12-01
2014-06-30$68.50K
10-Q · filed 2015-08-19
$168.26K
10-Q · filed 2015-08-19
$244.88K
derived: sum of 3 quarters · filed 2015-08-19
$300.34K
derived: sum of 4 quarters · filed 2015-08-19
2014-03-31$99.77K
10-Q · filed 2015-05-15
$176.38K
derived: sum of 2 quarters · filed 2015-05-15
$231.84K
derived: sum of 3 quarters · filed 2015-05-15
$295.20K
derived: sum of 4 quarters · filed 2015-05-15
$988.64K
10-Q · filed 2014-05-14
2013-12-31$76.61K
derived: 10-K 12 month − 10-Q 9 month · filed 2015-04-14
$132.08K
derived: sum of 2 quarters · filed 2015-04-14
$195.44K
derived: sum of 3 quarters · filed 2015-04-14
$267.06K
10-K · filed 2015-04-14
$888.87K
10-K · filed 2014-03-27
2013-09-30$55.47K
10-Q · filed 2014-11-13
$118.83K
derived: sum of 2 quarters · filed 2014-11-13
$190.45K
10-Q · filed 2014-11-13
$282.27K
derived: sum of 4 quarters · filed 2014-11-13
$812.26K
10-Q · filed 2013-11-08
2013-06-30$63.36K
10-Q · filed 2014-08-19
$134.99K
10-Q · filed 2014-08-19
$226.80K
derived: sum of 3 quarters · filed 2014-08-19
$290.87K
derived: sum of 4 quarters · filed 2014-08-19
$756.79K
10-Q/A · filed 2013-09-06
2013-03-31$71.63K
10-Q · filed 2014-05-14
$163.44K
derived: sum of 2 quarters · filed 2014-05-14
$227.51K
derived: sum of 3 quarters · filed 2014-05-14
$375.56K
derived: sum of 4 quarters · filed 2014-05-14
2012-12-31$91.82K
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-27
$155.89K
derived: sum of 2 quarters · filed 2014-03-27
$303.93K
derived: sum of 3 quarters · filed 2014-03-27
$448.03K
10-K · filed 2014-03-27
2012-09-30$64.07K
10-Q · filed 2013-11-08
$212.11K
derived: sum of 2 quarters · filed 2013-11-08
$356.21K
10-Q · filed 2013-11-08
2012-06-30$148.04K
10-Q/A · filed 2013-09-06
$292.14K
10-Q/A · filed 2013-09-06

Similar stocks

Stock NameCountryMarket CapPE Ratio
AMARIN CORP PLC\UK (AMRN)$0.005B-247.24
Xenetic Biosciences, Inc. (XBIO)United States$0.006B
ProPhase Labs, Inc. (PRPH)United States$0.006B-0.06
Dermata Therapeutics, Inc. (DRMA)United States$0.005B-0.62
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)United States$0.005B
Cadrenal Therapeutics, Inc. (CVKD)United States$0.004B-0.90
Pulmatrix, Inc. (PULM)United States$0.006B
Lakewood-Amedex Biotherapeutics Inc. (LABT)United States$0.004B
Ernexa Therapeutics Inc. (ERNA)United States$0.006B
60 DEGREES PHARMACEUTICALS, INC. (SXTP)United States$0.004B-0.59